Clinical Analysis of SYNGAP1 Variant-Related Neurodevelopmental Disorders in Chinese Children
Jia Zhang1,2, Yajun Shen1,2, Gong Xue1,2
1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Clinical Genetics
|March 31, 2026
Summary
This study details SYNGAP1-related neurodevelopmental disorders (SRDs) in Chinese children, highlighting severe developmental delay, high autism spectrum disorder (ASD) rates, and common epilepsy. Eyelid myoclonia is linked to drug-resistant epilepsy (DRE).
Area of Science:
- Genetics and Neurology
- Pediatric Neurodevelopmental Disorders
Background:
- SYNGAP1-related neurodevelopmental disorders (SRDs) are genetic conditions impacting brain development.
- Understanding SRD clinical phenotypes and genotype-phenotype correlations is crucial for effective management.
Purpose of the Study:
- To characterize clinical phenotypes in Chinese children with SRDs.
- To explore genotype-phenotype correlations within the SYNGAP1 gene.
- To guide optimal clinical management strategies for SRDs.
Main Methods:
- Retrospective collection of clinical data from 99 Chinese children with SRDs.
- Inclusion of genetic results, clinical features, EEG, cranial imaging, and treatment responses.
- Analysis of genotype-phenotype correlations using Pearson correlation and logistic regression.
Main Results:
- Predominant severe developmental delay (82.8%) and high autism spectrum disorder (ASD) comorbidity (60.6%) were observed.
- Epilepsy affected 68.7% of patients, with eyelid myoclonia being the most common seizure type (54.4%); ~33% developed drug-resistant epilepsy (DRE).
- Domain analysis revealed specific impacts: PH domain associated with myoclonic seizures, C2 domain with high epilepsy incidence, and SH3 domain with lower DRE incidence.
Conclusions:
- SRDs are characterized by severe developmental delay, high epilepsy incidence, and ASD comorbidity.
- Partial domain-specific genotype-phenotype associations exist, influencing clinical outcomes.
- Eyelid myoclonia is a negative prognostic indicator for epilepsy treatment response and DRE.


